T cells expressing NKG2D chimeric antigen receptors efficiently eliminate glioblastoma and cancer stem cells
Abstract Background Traditional therapies fail to cure most glioblastoma patients and the 5-year survival rate is less than 10%, highlighting need for new therapeutic approaches. The natural killer group 2 member D ligands (NKG2DLs) are highly expressed in glioblastomas and are considered promising...
Main Authors: | Dong Yang, Bin Sun, Hongjiu Dai, Wenxuan Li, Lan Shi, Peixian Zhang, Shirong Li, Xudong Zhao |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2019-07-01
|
Series: | Journal for ImmunoTherapy of Cancer |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s40425-019-0642-9 |
Similar Items
-
Chimeric antigen receptor T-cells for glioblastoma: The journey ahead
by: Sujith Kurian Joseph, et al.
Published: (2019-01-01) -
Clinical chimeric antigen receptor‐T cell therapy: a new and promising treatment modality for glioblastoma
by: Michael P Brown, et al.
Published: (2019-01-01) -
Chimeric antigen receptor T-cell therapy in glioblastoma: charging the T cells to fight
by: Craig A. Land, et al.
Published: (2020-11-01) -
Chimeric Antigen Receptor T-Cell Therapy in Glioblastoma: Current and Future
by: Long Li, et al.
Published: (2020-11-01) -
Novel high‐affinity EGFRvIII‐specific chimeric antigen receptor T cells effectively eliminate human glioblastoma
by: Rebecca C Abbott, et al.
Published: (2021-01-01)